Who are Imatinib Mesylate and Nilotinib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): imatinib (IM), Nilotinib 300 mg., DW6012(Dasidiem tab. 10/100mg), Dasatinib Tablets, TKI, ABL001.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/imatinib-mesylate-and-nilotinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Imatinib Mesylate and Nilotinib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Imatinib Mesylate and Nilotinib (Imatinib Mesylate and Nilotinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Oncology.

phase 3 Tyrosine kinase inhibitor BCR-ABL Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Imatinib Mesylate and Nilotinib (Imatinib Mesylate and Nilotinib) — University Hospital, Lille. Imatinib and nilotinib are tyrosine kinase inhibitors that block BCR-ABL and other oncogenic kinases to suppress abnormal cell proliferation in chronic myeloid leukemia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Imatinib Mesylate and Nilotinib TARGET	Imatinib Mesylate and Nilotinib	University Hospital, Lille	phase 3	Tyrosine kinase inhibitor	BCR-ABL
imatinib (IM)	imatinib (IM)	First Affiliated Hospital, Sun Yat-Sen University	marketed	Tyrosine kinase inhibitor	BCR-ABL, KIT, PDGFRA
Nilotinib 300 mg.	Nilotinib 300 mg.	King Abdullah International Medical Research Center	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL
DW6012(Dasidiem tab. 10/100mg)	DW6012(Dasidiem tab. 10/100mg)	Dong Wha Pharmaceutical Co. Ltd.	marketed	Tyrosine kinase inhibitor combination	BCR-ABL, SRC family kinases
Dasatinib Tablets	Dasatinib Tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL, SRC family kinases
TKI	TKI	Shenzhen TargetRx Co., Ltd.	phase 3	Tyrosine kinase inhibitor	Tyrosine kinases (e.g. EGFR, HER2, BCR-ABL)
ABL001	ABL001	Marlise Luskin, MD	phase 3	BCR-ABL allosteric inhibitor	BCR-ABL

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
Centre Leon Berard · 2 drugs in this class
AB Science · 2 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
Angion Biomedica Corp · 1 drug in this class
Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
Chang-Ming Huang, Prof. · 1 drug in this class
Deciphera Pharmaceuticals, LLC · 1 drug in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Imatinib Mesylate and Nilotinib — Competitive Intelligence Brief. https://druglandscape.com/ci/imatinib-mesylate-and-nilotinib. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab